Bio Path Holdings Inc's Customers Performance

Name: Bio Path Holdings Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

BPTH

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


BPTH's Source of Revenues		• List of BPTH Customers

for the same period Bio Path Holdings Inc

• List of BPTH Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Bio Path Holdings Inc's Comment on Sales, Marketing and Customers

News about Bio path Holdings inc Contracts

Expanding Horizons Bio-Path Holdings Ventures Into Obesity Treatment with Innovative DNAbilize Technology

Exploring New Frontiers in Obesity TreatmentIn a groundbreaking development, Bio-Path Holdings, Inc. a biotechnology firm renowned for its innovative cancer treatment solutions, announced the initiation of a new therapeutic program aimed at addressing obesity and related metabolic diseases. This initiative marks a significant milestone for the company as it utilizes its proprietary DNAbilize liposomal delivery and antisense technology, traditionally reserved for cancer therapies, for a non-cancer application. This strategic pivot signifies the company s ambitions to leverage its advanced technology s potential across various therapeutic areas, now embracing the pressing health issue of obesity. Understandin...

Bio-Path Holdings Unveiling Promising Clinical Progress and Ambitious Expansion Strategies in Overcoming Oncological ...

CSIMarket.com presents an overview of recent updates from Bio-Path Holdings, focusing on their clinical progress and expansion plans in the treatment of various cancer indications. The article highlights the positive results from ongoing phase 2 combination studies of Prexigebersen, specifically for the treatment of Acute Myeloid Leukemia (AML) in high-risk patients. These updates shed light on Bio-Path Holdings advancement towards effective therapies and highlight their commitment to improving patient outcomes. Bio-Path Holdings, a renowned pharmaceutical company, has recently provided a comprehensive clinical update and outlined their expansion plans for treating multiple cancer indications. The notable...

Bio-Path Holdings RNAi Therapies Show Promise in High-Risk and Resistant Acute Myeloid Leukemia Treatment

Bio-Path Holdings, a clinical-stage biotechnology company focused on developing RNAi nanoparticle-based therapies for cancer, recently presented positive data from an ongoing Phase 2 combination study of their drug candidate, Prexigebersen, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results of an interim analysis demonstrated significant clinical improvement and a tolerable safety profile for the Prexigebersen combination in high-risk patients with acute myeloid leukemia (AML).AML is a type of cancer that affects the bone marrow and blood. It is a rapidly progressing disease with a poor prognosis, particularly in high-risk patients who have genetic mutations associated with treat...

BPTH's Stock Performance relative to it's Customers

BPTH's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Bio path Holdings inc	0.00	0.00	-8.70	9
SUBTOTAL	0.00	0.00	0.00	-

Sources: Bio path Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bio path Holdings inc’s corporate clients.
For your research, we’ve provided 9 tables on Bio path Holdings inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.